For help on how to get the results you want, see our search tips.
2 results
Keyword Remove keyword
Categories
Human Remove Human filter
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Referrals Remove Referrals filter
Medicine type
Biosimilar Remove Biosimilar filter
Generic Remove Generic filter
Additional monitoring Remove Additional monitoring filter
Accelerated assessment Remove Accelerated assessment filter
Referral PRAC recommendation
Variation Remove Variation filter
Risk minimisation measures Remove Risk minimisation measures filter
Referral safety status
Yes Remove Yes filter
Referral decision making model
PRAC-CHMP-EC Remove PRAC-CHMP-EC filter
Referral authorisation model
Centrally authorised product(s) Remove Centrally authorised product(s) filter
-
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020 -
List item
Referral: Janus kinase inhibitors (JAKi) (updated)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/05/2023